JP2020537659A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537659A5 JP2020537659A5 JP2020521541A JP2020521541A JP2020537659A5 JP 2020537659 A5 JP2020537659 A5 JP 2020537659A5 JP 2020521541 A JP2020521541 A JP 2020521541A JP 2020521541 A JP2020521541 A JP 2020521541A JP 2020537659 A5 JP2020537659 A5 JP 2020537659A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- virus
- mycoplasmataceae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 241000204034 Mycoplasmataceae Species 0.000 claims description 14
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000003612 virological effect Effects 0.000 claims description 8
- 229940123424 Neuraminidase inhibitor Drugs 0.000 claims description 6
- 241000700605 Viruses Species 0.000 claims description 6
- 239000002911 sialidase inhibitor Substances 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 241001112741 Bacillaceae Species 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 4
- 241000588921 Enterobacteriaceae Species 0.000 claims description 4
- 241001248479 Pseudomonadales Species 0.000 claims description 4
- 206010042566 Superinfection Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical group CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims description 4
- 241000712431 Influenza A virus Species 0.000 claims description 3
- 241000713196 Influenza B virus Species 0.000 claims description 3
- 241000947836 Pseudomonadaceae Species 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 3
- 241000606069 Chlamydiaceae Species 0.000 claims description 2
- QNRRHYPPQFELSF-CNYIRLTGSA-N Laninamivir Chemical compound OC[C@@H](O)[C@@H](OC)[C@@H]1OC(C(O)=O)=C[C@H](N=C(N)N)[C@H]1NC(C)=O QNRRHYPPQFELSF-CNYIRLTGSA-N 0.000 claims description 2
- 241000589246 Legionellaceae Species 0.000 claims description 2
- 241000606752 Pasteurellaceae Species 0.000 claims description 2
- 241000295644 Staphylococcaceae Species 0.000 claims description 2
- 241000194018 Streptococcaceae Species 0.000 claims description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 2
- 229950004244 laninamivir Drugs 0.000 claims description 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 2
- 229960003752 oseltamivir Drugs 0.000 claims description 2
- 229960002194 oseltamivir phosphate Drugs 0.000 claims description 2
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims description 2
- 229960001084 peramivir Drugs 0.000 claims description 2
- 229960001028 zanamivir Drugs 0.000 claims description 2
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 241000606161 Chlamydia Species 0.000 description 2
- 241000589248 Legionella Species 0.000 description 2
- 208000007764 Legionnaires' Disease Diseases 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023018912A JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LULU100487 | 2017-10-17 | ||
| LU100487 | 2017-10-17 | ||
| PCT/EP2018/078335 WO2019076947A1 (en) | 2017-10-17 | 2018-10-17 | NEW MEK INHIBITOR FOR THE TREATMENT OF VIRAL AND BACTERIAL INFECTIONS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018912A Division JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537659A JP2020537659A (ja) | 2020-12-24 |
| JP2020537659A5 true JP2020537659A5 (enExample) | 2021-09-16 |
| JP7227967B2 JP7227967B2 (ja) | 2023-02-22 |
Family
ID=60484427
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020521541A Active JP7227967B2 (ja) | 2017-10-17 | 2018-10-17 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2023018912A Active JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A Pending JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023018912A Active JP7618276B2 (ja) | 2017-10-17 | 2023-02-10 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
| JP2024228526A Pending JP2025031917A (ja) | 2017-10-17 | 2024-12-25 | ウイルス感染および細菌感染の処置のための新規ｍｅｋ阻害剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11903917B2 (enExample) |
| EP (2) | EP3697405B1 (enExample) |
| JP (3) | JP7227967B2 (enExample) |
| KR (1) | KR102848960B1 (enExample) |
| CN (2) | CN111479566B (enExample) |
| AU (2) | AU2018351475A1 (enExample) |
| CA (1) | CA3078424A1 (enExample) |
| CY (1) | CY1124507T1 (enExample) |
| DK (1) | DK3697405T3 (enExample) |
| EA (1) | EA202090693A1 (enExample) |
| ES (2) | ES3041322T3 (enExample) |
| HR (1) | HRP20211252T1 (enExample) |
| HU (1) | HUE055738T2 (enExample) |
| LT (1) | LT3697405T (enExample) |
| MX (2) | MX2020003473A (enExample) |
| PL (1) | PL3697405T3 (enExample) |
| PT (1) | PT3697405T (enExample) |
| SI (1) | SI3697405T1 (enExample) |
| WO (1) | WO2019076947A1 (enExample) |
| ZA (1) | ZA202002069B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| LU101183B1 (en) * | 2019-04-16 | 2020-10-16 | Atriva Therapeutics Gmbh | Novel mek-inhibitor for the treatment of viral and bacterial infections |
| WO2021037956A1 (en) | 2019-08-27 | 2021-03-04 | Atriva Therapeutics Gmbh | Combinations of mek inhibitors with cap-dependent endonuclease inhibitors |
| AU2020362953A1 (en) * | 2019-10-08 | 2022-04-14 | Atriva Therapeutics Gmbh | MEK inhibitors for the treatment of hantavirus infections |
| ES2995196T3 (en) * | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
| CN112957361B (zh) * | 2021-03-24 | 2022-07-29 | 中国科学院武汉病毒研究所 | 曲美替尼在制备抗沙粒病毒的抗病毒制剂中的应用 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| IL144103A0 (en) | 1999-01-07 | 2002-05-23 | Warner Lambert Co | Antiviral method using mek inhibitors |
| CN1373660A (zh) | 1999-07-16 | 2002-10-09 | 沃尼尔·朗伯公司 | 使用mek抑制剂治疗慢性疼痛的方法 |
| DE10017480A1 (de) | 2000-04-07 | 2001-10-11 | Transmit Technologietransfer | Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren |
| JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル |
| DE10300222A1 (de) | 2003-01-03 | 2004-07-15 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Verwendung von Wirksubstanzen zur Prophylaxe und/oder Therapie von Viruserkrankungen |
| JP2007055983A (ja) | 2005-08-26 | 2007-03-08 | Tokyo Univ Of Science | 細胞内に侵入した病原性細菌に起因する疾患の予防・改善剤 |
| CA2807510A1 (en) * | 2010-08-05 | 2012-02-09 | Case Western Reserve University | Inhibitors of erk for developmental disorders of neuronal connectivity |
| CN109276716B (zh) | 2012-10-08 | 2021-06-08 | 归属疗法有限公司 | 用在病毒性疾病的治疗中的mek抑制剂 |
| EA039897B1 (ru) | 2014-05-16 | 2022-03-24 | Атрива Терепьютикс Гмбх | Применение ингибитора мек для лечения коинфекции, включающей бактериальную инфекцию и инфекцию, вызванную вирусом гриппа |
| US11903917B2 (en) * | 2017-10-17 | 2024-02-20 | Atriva Therapeutics Gmbh | MEK-inhibitor for the treatment of viral and bacterial infections |
| AU2020362953A1 (en) | 2019-10-08 | 2022-04-14 | Atriva Therapeutics Gmbh | MEK inhibitors for the treatment of hantavirus infections |
| ES2995196T3 (en) | 2020-05-20 | 2025-02-07 | Atriva Therapeutics Gmbh | Pd-0184264 for the treatment of coronavirus infections and/or covid-19 cytokine storm |
-
2018
- 2018-10-17 US US16/756,720 patent/US11903917B2/en active Active
- 2018-10-17 MX MX2020003473A patent/MX2020003473A/es unknown
- 2018-10-17 HU HUE18800045A patent/HUE055738T2/hu unknown
- 2018-10-17 ES ES21185183T patent/ES3041322T3/es active Active
- 2018-10-17 ES ES18800045T patent/ES2883639T3/es active Active
- 2018-10-17 PT PT188000459T patent/PT3697405T/pt unknown
- 2018-10-17 CN CN201880081184.5A patent/CN111479566B/zh active Active
- 2018-10-17 WO PCT/EP2018/078335 patent/WO2019076947A1/en not_active Ceased
- 2018-10-17 EA EA202090693A patent/EA202090693A1/ru unknown
- 2018-10-17 CA CA3078424A patent/CA3078424A1/en active Pending
- 2018-10-17 EP EP18800045.9A patent/EP3697405B1/en active Active
- 2018-10-17 PL PL18800045T patent/PL3697405T3/pl unknown
- 2018-10-17 JP JP2020521541A patent/JP7227967B2/ja active Active
- 2018-10-17 KR KR1020207013451A patent/KR102848960B1/ko active Active
- 2018-10-17 EP EP21185183.7A patent/EP3973960B1/en active Active
- 2018-10-17 SI SI201830351T patent/SI3697405T1/sl unknown
- 2018-10-17 AU AU2018351475A patent/AU2018351475A1/en not_active Abandoned
- 2018-10-17 HR HRP20211252TT patent/HRP20211252T1/hr unknown
- 2018-10-17 CN CN202410133936.5A patent/CN118141795A/zh active Pending
- 2018-10-17 LT LTEPPCT/EP2018/078335T patent/LT3697405T/lt unknown
- 2018-10-17 DK DK18800045.9T patent/DK3697405T3/da active
-
2020
- 2020-05-04 ZA ZA2020/02069A patent/ZA202002069B/en unknown
- 2020-07-13 MX MX2022016066A patent/MX2022016066A/es unknown
-
2021
- 2021-08-24 CY CY20211100757T patent/CY1124507T1/el unknown
-
2023
- 2023-02-10 JP JP2023018912A patent/JP7618276B2/ja active Active
-
2024
- 2024-02-16 US US18/443,904 patent/US20240245637A1/en active Pending
- 2024-08-16 AU AU2024205853A patent/AU2024205853A1/en active Pending
- 2024-12-25 JP JP2024228526A patent/JP2025031917A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020537659A5 (enExample) | ||
| HRP20211252T1 (hr) | Novi mek-inhibitor za liječenje virusnih i bakterijskih infekcija | |
| CN102325532B (zh) | 用于减轻肺部炎症的左氧氟沙星吸入剂 | |
| JP2015534562A5 (enExample) | ||
| JP2018021046A5 (enExample) | ||
| JP2012126736A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| JP2019524865A5 (enExample) | ||
| JP2015517489A5 (enExample) | ||
| JP2015529225A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| JP2021152008A5 (enExample) | ||
| IL307992A (en) | Parasitic formulations containing isoxazoline and methods for treating blepharitis | |
| CN110769824B (zh) | 用于治疗和/或预防细菌继发性感染的il-8抑制剂 | |
| CN115666626A (zh) | 一种治疗阿尔茨海默病的方法和药物 | |
| JP2017526627A5 (enExample) | ||
| JP2017526714A5 (enExample) | ||
| HRP20211749T1 (hr) | Pentanske kiseline supstituirane pirolo-[2-3,b]pirimidin-piridinima za liječenje virusnih infekcija influencom | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| JP2020524689A5 (enExample) | ||
| JP2020529995A5 (enExample) | ||
| CL2021000160A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
| JP2018526345A5 (enExample) | ||
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada |